PLSEPulse Biosciences, Inc.
$53.80+206% 1Y
$53.80
$12.6652 weeks$55.20
PLSE in its own filings
PLSE's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
300
Events found in the filings · across 638 filings · the record starts in 2016
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 7, 2026
Most recent filing · Form 8-K
- Record starts
- Jan 19, 2016
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountanthistorical
- 2018-04-11
- Late periodic reportpast_3y
- 2024-08-15
- Delisting notice / listing-rule failurehistorical
- 2018-07-31
- SEC comment-letter activity49 occurrences
- 2026-02-25
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 7, 2026On October 7, 2026, Pulse Biosciences, Inc. (the “Company”) announced that it had achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study evaluating the Company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation (the “Study”)Other event · Form 8-K
- Sep 15, 2026On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho, shares of the Company’s common stock, par …Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) announced completion of patient enrollment in its PRECISE-BTN clinical study evaluating the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (the “Study”)Other event · Form 8-K
- Aug 6, 2026On August 6, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho shares of the Company’s common stock, par value …Material agreement entered · Form 8-K
- Jul 29, 2026On July 29, 2026, Pulse Biosciences, Inc. (the “Company”) announced surpassing the enrollment midpoint of its NANOPULSE-AF clinical study ("Study"), a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant …Other event · Form 8-K
- Jun 10, 2026On June 10, 2026, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing that it will deliver an irrevocable election to redeem the outstanding common stock warrants issued on July 3, 2024 (“Warrants”) in connection with the Company’s rights offering pursuant to its Registration Statement on Form …Other event · Form 8-K
- May 6, 2026On May 5, 2026, the Board of Directors of Pulse Biosciences, Inc. (the “Company”) approved resolutions permitting TD Securities (USA) LLC, as sales agent (“TD Cowen”), to sell Company common stock to one or more Company affiliates pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and …Other event · Form 8-K
- May 4, 2026On May 4, 2026, Pulse Biosciences, Inc. (the “Company”) announced accelerated enrollment timelines in its NANOPULSE-AF clinical trial.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Instruments & Supplies
Ranks #21 of 21 by RyuScore